前沿生物2025年净利预亏2.55亿元至2.9亿元

Core Viewpoint - Frontier Biotech (688221) anticipates a net profit loss of approximately -255 million to -290 million yuan for 2025, indicating an increase in losses compared to the previous year [1] Financial Performance - The expected net profit loss for 2025 is primarily due to the absence of investment income from the disposal of subsidiary equity, which generated 71.8365 million yuan in 2024 [1] - The projected operating revenue for 2025 is estimated to be between 140 million to 145 million yuan, reflecting a year-on-year increase of 8.13% to 11.99% [1] Revenue Sources - The anticipated revenue will mainly come from the sales of the innovative anti-HIV drug Aikening (generic name: Aibowei Tai), the agency product Viread (tenofovir disoproxil fumarate), and the recently approved far-infrared therapy patch (Xiaoyan Yi Tie) [1]